Cargando…

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants

Low-cost, refrigerator-stable COVID-19 vaccines will facilitate global access and improve vaccine coverage in low- and middle-income countries. To this end, subunit-based approaches targeting the receptor-binding domain (RBD) of SARS-CoV-2 Spike protein remain attractive. Antibodies against RBD neut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bajoria, Sakshi, Kaur, Kawaljit, Kumru, Ozan S., Van Slyke, Greta, Doering, Jennifer, Novak, Hayley, Rodriguez Aponte, Sergio A., Dalvie, Neil C., Naranjo, Christopher A., Johnston, Ryan S., Silverman, Judith Maxwell, Kleanthous, Harry, Love, J. Christopher, Mantis, Nicholas J., Joshi, Sangeeta B., Volkin, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621007/ https://www.ncbi.nlm.nih.gov/pubmed/35666264 http://dx.doi.org/10.1080/21645515.2022.2079346

Ejemplares similares

Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018(TM) Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen
por: Bajoria, Sakshi, et al.
Publicado: (2023)

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants
por: Rodriguez-Aponte, Sergio A., et al.
Publicado: (2023)

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines
por: Kumru, Ozan S., et al.
Publicado: (2023)

The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop
por: Hempel, Heidi, et al.
Publicado: (2023)

Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
por: Li, Yulei, et al.
Publicado: (2023)

A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
por: An, Yaling, et al.
Publicado: (2022)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
por: Wei, Dong, et al.
Publicado: (2022)

Understanding the impact of rapid antigen tests on SARS-CoV-2 transmission in the fifth wave of COVID-19 in Hong Kong in early 2022
por: Du, Zhanwei, et al.
Publicado: (2022)

Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2
por: Rodrigues, Kristen A., et al.
Publicado: (2021)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants
por: Fan, Feng, et al.
Publicado: (2023)

Characterization of antigen adjuvant interactions in polyacrylate adjuvanted vaccines
por: Dinadayala, Premkumar, et al.
Publicado: (2022)

Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens
por: Agarwal, Sanjeev, et al.
Publicado: (2020)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™
por: Xu, Senyu, et al.
Publicado: (2023)

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
por: Dalvie, Neil C., et al.
Publicado: (2021)

SARS-CoV-2 vaccination in the context of original antigenic sin
por: Petráš, Marek, et al.
Publicado: (2021)

Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines
por: Honda-Okubo, Yoshikazu, et al.
Publicado: (2021)

SARS-CoV-2 sublingual vaccine with RBD antigen and poly(I:C) adjuvant: Preclinical study in cynomolgus macaques
por: Yamamoto, Tetsuro, et al.
Publicado: (2023)

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant–Antigen Codelivery
por: Wang, Zhi-Biao, et al.
Publicado: (2020)

Fusing Antigens and Adjuvants into Traceless Nanogels
por: De Geest, Bruno G.
Publicado: (2020)

CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015)

The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
por: Brzuska, Gabriela, et al.
Publicado: (2023)

Assembly and Immunological Processing of Polyelectrolyte Multilayers Composed of Antigens and Adjuvants
por: Chiu, Yu-Chieh, et al.
Publicado: (2016)

Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens
por: Sawant, Nishant, et al.
Publicado: (2021)

Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus
por: Dalvie, Neil C., et al.
Publicado: (2021)

CpG Oligonucleotides as Cancer Vaccine Adjuvants
por: Shirota, Hidekazu, et al.
Publicado: (2015)

Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine
por: Kaur, Kawaljit, et al.
Publicado: (2021)

Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen
por: Milley, Bob, et al.
Publicado: (2016)

SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
por: Dalvie, Neil C., et al.
Publicado: (2022)

Antibody-Antigen-Adjuvant Conjugates Enable Co-Delivery of Antigen and Adjuvant to Dendritic Cells in Cis but Only Have Partial Targeting Specificity
por: Kreutz, Martin, et al.
Publicado: (2012)

COVID-19 risk perception, cognitive dissonance, and vaccine hesitancy
por: Equils, Ozlem, et al.
Publicado: (2023)

Licensed liposomal vaccines and adjuvants in the antigen delivery system
por: Krasnopolsky, Yuriy, et al.
Publicado: (2022)

CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
por: Li, Yibo, et al.
Publicado: (2023)

RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge
por: Wong, Ting Y., et al.
Publicado: (2022)

Hybrid immunity and protection against infection during the Omicron wave in Malta
por: Cauchi, John Paul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_151tu53poav8dv31j87ngaesfq